Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KenvueKVUE -1.28%70 EBIT per Share is $1.37 as of Mar. 2026. GuruFocus rates KVUE with a GF Score™ of 70/100 and a GF Value™ of $20.40 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,581 Consumer Packaged Goods companies, Kenvue ranks worse than 63.63% on this metric.
Kenvue's EBIT per Share for the
three
months ended in Mar. 2026 was $0.41.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.37.
During the past 12 months, the average EBIT per Share Growth Rate of Kenvue was 13.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -0.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -3.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Kenvue's EBIT per Share or its related term are showing as below:
KVUE'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -5.2 Med: -2.75 Max: 3.9
Current: -0.3
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Kenvue was 3.90% per year. The lowest was -5.20% per year. And the median was -2.75% per year.
KVUE's 3-Year EBIT Growth Rate is ranked worse than 63.63% of 1581
companies
in the Consumer Packaged Goods industry
Industry Median: 6.9
vs KVUE: -0.30
Kenvue's EBIT for the
three
months ended in Mar. 2026 was $778 Mil.
Kenvue (NYSE:KVUE) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Kenvue EBIT per Share Related Terms
Kenvue EBIT per Share Historical Data
* Premium members only.
The historical data trend for Kenvue's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.37
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kenvue (KVUE) has a EBIT per Share of $1.37 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Kenvue and its competitors. According to the industry distribution chart, Kenvue ranks #1006 out of 1581 companies in the Consumer Packaged Goods industry, placing it in the top 63.6%.
Is Kenvue's EBIT per Share too high?
Kenvue's current EBIT per Share is $1.37. The Consumer Packaged Goods industry median EBIT per Share is 6.90. Kenvue's value of $1.37 is 80.1% below this industry median. Based on the distribution chart, Kenvue ranks #1006 out of 1581 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Kenvue has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kenvue's EBIT per Share compare to KMB and EL?
According to the Consumer Packaged Goods industry distribution chart, Kenvue ranks #1006 out of 1581 companies for EBIT per Share. This places Kenvue in the lower half of its industry. The industry median EBIT per Share is 6.90. Kenvue's value of $1.37 is 80.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Consumer Packaged Goods company?
The median EBIT per Share among Consumer Packaged Goods companies is 6.90, based on 1,581 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kenvue's current EBIT per Share of $1.37 is 80.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Kenvue and its competitors. For the Consumer Packaged Goods industry, the median EBIT per Share is 6.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kenvue's current EBIT per Share is $1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kenvue stock overvalued right now?
Based on GuruFocus' analysis, Kenvue (KVUE) is currently considered Fairly Valued. The stock's GF Value™ is $20.40, compared to a current price of $19.23 — trading 5.7% below its estimated fair value. The current EBIT per Share is $1.37 and 80.1% below the Consumer Packaged Goods industry median of 6.90. Kenvue's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Kenvue (KVUE), the current EBIT per Share is $1.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kenvue (KVUE) Overvalued in 2026?
Based on GuruFocus' analysis, Kenvue stock appears to be undervalued.
The current stock price of $19.23 is trading 5.7% below its estimated GF Value™ of $20.40.
GuruFocus considers Kenvue to be Fairly Valued.
Key valuation signals for KVUE:
EBIT per Share: $1.37
GF Value™: $20.40 vs. price of $19.23 (5.7% below fair value)
Industry Position: 80.1% below the Consumer Packaged Goods median (#1006 of 1581)
No single metric tells the full story. See the KVUE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
70GF Score
Get the complete analysis for KVUE
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KVUE has been successfully added to your 
